The Effect of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors on Cardiovascular Outcomes in Cancer Patients With Type 2 Diabetes Mellitus: A Systematic Review. Here, SLC5A2 is linked to type 2 diabetes mellitus.